Singapore HSA goes live with LORENZ eCTD Reviewing Solution
Frankfurt/Main, Germany and Singapore, October 2025 // The Singapore Health Sciences Authority (HSA) has officially launched its new eCTD Portal for test submissions, marking a major milestone in its efforts to modernize drug evaluation and approval processes. The system, powered by the consortium of LORENZ Life Sciences Group, VRG Pte. Ltd., and Websparks Pte. Ltd., is now live and available for industry use.
The complete solution, built on LORENZ’s proven applications docuBridge, eValidator, and Automator, combined with a portal offering from Websparks, enables HSA to receive, validate, and review eCTD dossiers. It will also serve as a foundation for the development of a regional schema and eCTD specification.
The go-live follows HSA’s earlier announcement in 2023, when the consortium was selected to deliver the eCTD reviewing solution. Since then, the partners have worked closely with HSA to provide project management, consulting, training, and support throughout the implementation, including release of the SG-HSA Specification v1.0 for eCTD Implementation in Singapore in September 2024.
“We are proud to see this joint effort come to life,” says Wolfgang Witzel, President of LORENZ Life Sciences Group. “Going live with the eCTD system in Singapore underscores our ongoing mission to support regulatory authorities worldwide in adopting advanced technologies that make submissions faster, more efficient, and more reliable.”
Initially, the new system will support new drug applications, generic drug applications, and their corresponding Drug Master File (DMF) submissions. Its gradual introduction allows industry stakeholders to test and familiarize themselves with the system before broader adoption.
This launch represents another important step in LORENZ’s global footprint of supporting regulatory authorities, including Collaboration Consortiums like ACCESS, (with HSA Singapore, Health Canada, TGA Australia, Swissmedic Switzerland, MHRA UK) and agencies, in the USA, Japan and Germany.